Celgene Corp (CELG)

125.54
2.40 1.90
NASDAQ : Health Care
Prev Close 123.15
Open 124.00
Day Low/High 123.75 / 126.22
52 Wk Low/High 92.98 / 137.54
Volume 3.98M
Avg Volume 3.72M
Exchange NASDAQ
Shares Outstanding 777.97M
Market Cap 95.11B
EPS 2.60
P/E Ratio 49.10
Div & Yield N.A. (N.A)

Latest News

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season

Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.

Momentum Is Fading

Momentum Is Fading

Forget financials, stick to steady growers.

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Apple, Allergan and Western Digital.

Biotechs Catching Their Breath: Cramer's 'Off The Charts'

Biotechs Catching Their Breath: Cramer's 'Off The Charts'

Some recent high-flying biotechs may be preparing for their next surge.

The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)

The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)

Political negatives keep popping up, forcing us to rethink the Trump trade, says Jim Cramer.

Allergan and Celgene Are in Peak Health

Allergan and Celgene Are in Peak Health

These stocks should be part of a strong first-quarter earnings season.

Celgene Notified Of ANDA Filing For POMALYST®

Celgene Notified Of ANDA Filing For POMALYST®

Celgene Corporation (NASDAQ:CELG) has received a Paragraph IV Notice Letter advising that Teva Pharmaceuticals USA, Inc.

Celgene Corporation To Announce First Quarter 2017 Results On April 27, 2017

Celgene Corporation To Announce First Quarter 2017 Results On April 27, 2017

Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, April 27, 2017 at 9 a.

So Far So Good : Cramer's 'Mad Money' Recap (Friday 3/31/17)

So Far So Good : Cramer's 'Mad Money' Recap (Friday 3/31/17)

The amazing first quarter didn't rely just on Trump.

Getting It Done; Markets Love Seniors: Jim Cramer's Best Blog

Getting It Done; Markets Love Seniors: Jim Cramer's Best Blog

Jim Cramer ponders how Breen is getting it done for DuPont, and discusses why the markets love seniors so gosh darn much.

Halliburton, Schlumberger, Alcoa, Celgene:'Mad Money' Lightning Round (3/29/17)

Halliburton, Schlumberger, Alcoa, Celgene:'Mad Money' Lightning Round (3/29/17)

Jim Cramer is bullish on Halliburton, Schlumberger, Cypress Semiconductor and Celgene

This Market Loves Tech: Cramer's 'Mad Money' Recap (Wednesday 3/29/17)

This Market Loves Tech: Cramer's 'Mad Money' Recap (Wednesday 3/29/17)

Tech's organic growth and visibility has been apparent all year, says Jim Cramer.

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen

The Roche drug, Ocrevus, secured FDA approval for two forms of multiple sclerosis.

Twitter, Netflix, MetLife: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

Doug Kass shares his thoughts on Twitter and talks about Sears.

Why Concert Pharmaceuticals Is Music to Investors' Ears

Why Concert Pharmaceuticals Is Music to Investors' Ears

This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.

Celgene Has Cure for Market Blues

Celgene Has Cure for Market Blues

Strong biotech stock has surged since November and is close to all-time highs.

Chart of the Day: Celgene

This name is within about 10% of all-time highs.

Dow, S&P 500 Retreat From Rally as Health Care Selloff Interrupts Fed Boost

Dow, S&P 500 Retreat From Rally as Health Care Selloff Interrupts Fed Boost

Investor sentiment soured on Thursday as a selloff in health care challenges optimism over the Federal Reserve's decision to raise interest rates.

S&P 500 Trades Lower as Health Care Sells Off, Crude Fluctuates

S&P 500 Trades Lower as Health Care Sells Off, Crude Fluctuates

Stocks are slightly lower by early afternoon Thursday as a selloff in health care challenges optimism over the Federal Reserve's decision to raise interest rates.

Stocks Extend Declines as Biogen Leads Health Care Selloff

Stocks Extend Declines as Biogen Leads Health Care Selloff

Early morning gains quickly evaporate on Thursday as a selloff in health care overshadows the Federal Reserve's decision a day earlier to raise interest rates.

Cramer: The Airlines and Health-Care Names Are Really Soaring

Cramer: The Airlines and Health-Care Names Are Really Soaring

This reversal has been incredible to watch.

It's Time to Add Credit Suisse's Top 10 Stocks for 2017 to Your Portfolio

It's Time to Add Credit Suisse's Top 10 Stocks for 2017 to Your Portfolio

Research firm Credit Suisse has put together a list of 140 "top ideas" covered by their analysts.

Credit Suisse's Top 10 Stocks for 2017

Credit Suisse's Top 10 Stocks for 2017

Companies like Apple, Facebook, J.P. Morgan and others are among Credit Suisse's top picks for 2017.

Allergan, Schlumberger, Caterpillar: Doug Kass' Views

Allergan, Schlumberger, Caterpillar: Doug Kass' Views

Doug Kass shares his thoughts on Allergan, and says that Caterpillar remains purr-fect for shorting.

Celgene's Deep Pipeline Can Reassure Investors

Celgene's Deep Pipeline Can Reassure Investors

This biotech company is trading at a bargain compared to its peer group.

These Trends Aren't Your Friends

There are signs of how narrow the market has become.

Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement Versus Placebo In Trial Of Patients With Moderate Plaque Psoriasis Who Were Naïve To Systemic And Biologic Therapy

Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement Versus Placebo In Trial Of Patients With Moderate Plaque Psoriasis Who Were Naïve To Systemic And Biologic Therapy

Celgene Corporation (NASDAQ:CELG) today announced that results from its phase 4 UNVEIL trial evaluating OTEZLA ® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with...

Celgene To Present New Data From Clinical Trials On Oral OTEZLA® (apremilast) At American Academy Of Dermatology Congress

Celgene To Present New Data From Clinical Trials On Oral OTEZLA® (apremilast) At American Academy Of Dermatology Congress

Celgene Corporation (NASDAQ:CELG) today announced that findings from ongoing clinical trials of OTEZLA ® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), conducted in patients with...